anti-angiogenesis

Show results for

Unknown (4027)
Transcriptomics (335)
Genomics (329)
Proteomics (48)
Clinical (17)
Other (9)
Genomic (3)
Metabolomics (3)
Models (1)
Methylation profiling (1)

Organisms

Homo sapiens (214)
Mus musculus (148)
Homo sapiens (35)
Mus musculus (35)
Rattus norvegicus (20)
Danio rerio (5)
Salmo salar (2)
Betapolyomavirus hominis (2)
Betapolyomavirus macacae (2)
Human alphaherpesvirus 1 (2)
Human betaherpesvirus 5 (2)
Human gammaherpesvirus 8 (2)
Human immunodeficiency virus 1 (2)
JC polyomavirus (2)
Murid gammaherpesvirus 4 (2)
human gammaherpesvirus 4 (2)
Bos taurus (1)
Caenorhabditis elegans (1)
Cavia porcellus (1)
Drosophila melanogaster (1)
Human alphaherpesvirus 2 (1)
Merkel cell polyomavirus (1)
Murid betaherpesvirus 1 (1)
Mus (1)
Mus musculus cytomegalovirus 2 (1)
Oncorhynchus mykiss (1)
Ovis aries (1)
synthetic construct (1)
Anaplasma sp. Goat50/1 (1)
Anaplasma sp. goatC/1 (1)

Organisms

Homo sapiens (143)
Mus musculus (112)
Rattus norvegicus (8)
Cavia porcellus (1)
Mus (1)
Salmo salar (1)
Bos taurus (1)
Ovis aries (1)
mouse gut metagenome (1)
Danio rerio (1)

Repository

ENA (300)
geo (246)
biostudies-arrayexpress (120)
pride (35)
EGA (8)
iProX (7)
MassIVE (6)
dbGaP (3)
MetaboLights (3)
BioModels (1)

Tissue

Cell culture (9)
Endothelial cell (4)
Epithelial cell (3)
Colon (2)
Vitreous humor (2)
Adult endothelial progenitor cell (1)
Blood (1)
Blood cell (1)
Bone marrow (1)
Brain microvascular endothelial cell (1)
Cell suspension culture (1)
Cerebral artery (1)
Cerebral cortex (1)
Fibroblast (1)
Hepatocyte (1)
Hippocampus (1)
Kidney (1)
Leukocyte (1)
Lung (1)
Macrophage (1)
Malignant cell (1)
Mesenchymal cell (1)
Microglial cell (1)
Monocyte (1)
Ovary (1)
Pancreas (1)
Retinal pigment epithelium cell (1)
Umbilical vein (1)
Venom (1)

Disease

Colorectal Neoplasms (10)
Colorectal cancer (2)
Breast cancer (2)
Lung cancer (2)
Renal cancer (1)
Serous ovarian cancer (1)
Normal (1)
Small cell lung cancer (1)
Liver Neoplasms (1)
Inflammatory Bowel Diseases (1)
Glioblastoma (1)
Carcinoma (1)
Colorectal cancer (1)
Atherosclerosis (1)
Brain ischemia (1)
Diabetic retinopathy (1)
Glioblastoma (1)
Kidney cancer (1)
Malignant neoplasm of ovary (1)
Pancreatic cancer (1)
Proliferative diabetic retinopathy (1)
Prostate adenocarcinoma (1)
Ulcerative colitis (1)

Technology Type

Mass Spectrometry (35)
Shotgun proteomics (15)
Bottom-up proteomics (6)
Data-dependent acquisition (4)
SWATH MS (4)
Data-independent acquisition (3)
Top-down proteomics (3)
Mass spectrometry (2)
Mass spectrometry assay (1)
Affinity purification coupled with mass spectrometry proteomics (1)
DiaPASEF (1)
Gel-based experiment (1)
HDMSE (1)

Instrument Platform

Illumina HiSeq 4000 (3)
LTQ Orbitrap Elite (2)
NextSeq 500 (1)
LTQ Orbitrap Velos (1)
Orbitrap Exploris 480 (1)
Q Exactive (1)
TimsTOF Pro (1)
MS Imaging - (1)
Liquid Chromatography MS - negative - reverse-phase (1)
Liquid Chromatography MS - positive - reverse-phase (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)
Liquid Chromatography MS - negative - hilic (1)
Liquid Chromatography MS - positive - hilic (1)

Publication Date

2025 (55)
2026 (39)
2023 (33)
2014 (31)
2024 (29)
2022 (25)
2013 (24)
2021 (21)
2015 (20)
2008 (18)
2010 (17)
2020 (16)
2016 (16)
2011 (16)
2009 (13)
2012 (12)
2017 (9)
2019 (7)
2007 (6)
2018 (5)
2006 (2)
2005 (2)
2004 (1)

CHEBI ID

CHEBI:38263 (1)
CHEBI:16450 (1)
CHEBI:28683 (1)
CHEBI:16680 (1)
CHEBI:15356 (1)
CHEBI:16856 (1)
CHEBI:17858 (1)
CHEBI:24898 (1)
CHEBI:16811 (1)
CHEBI:27570 (1)
CHEBI:73024 (1)
CHEBI:17126 (1)
CHEBI:29016 (1)
CHEBI:53210 (1)
CHEBI:16027 (1)
CHEBI:16668 (1)
CHEBI:28300 (1)
CHEBI:17822 (1)
CHEBI:28044 (1)
CHEBI:6650 (1)
CHEBI:18237 (1)
CHEBI:21557 (1)
CHEBI:15891 (1)

Metabolite Name

Theronine (1)
Adenosylhomocysteine (1)
Acetyl-methionine (1)
Glutathione (reduced) (1)
Hypotaurine (1)
IsoLeucine (1)
Deoxyuridine (1)
Cysteine (1)
GSSG (1)
Serine (1)
Taurine (1)
Malic acid (1)
Glutamine (1)
Glutamate (1)
Methionine (1)

First Public Date

2025 (52)
2014 (50)
2024 (40)
2026 (35)
2023 (29)
2021 (21)
2022 (19)
2020 (13)
2017 (12)
2015 (9)
2019 (8)
2016 (7)
2018 (5)

Modelling Approach

Ordinary differential equation model (1)

Study status

Completed (9)
Not provided (3)
Not yet recruiting (2)
Recruiting (2)
Terminated (1)

Lab affiliation

School of Optometry, The Hong Kong Polytechnic University (2)
ULB - Faculty of PHARMACY RD3 - Pharmacognosy, Bioanalysis & Drug Discovery Unit & Analytical Platform of the Faculty of Pharmacy (2)
(1) Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven, B-3000, Belgium; (2) Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Center, VIB, Leuven, B-3000, Belgium (1)
Additional Professor, Deptt. of Medical Oncology (Lab), Dr BRAIRCH, AIIMS, New Delhi (1)
Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (1)
China Pharmaceutical University (1)
Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Hong Kong S.A.R., China (1)
Department of Biochemistry and Biophysics University of North Carolina Chapel Hill, NC USA (1)
Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark. (1)
Department of Genetics, Medical College of Soochow University, Suzhou 215123, China. (1)
Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (1)
Forschungsinstitut für Frauengesundheit Universitäts- Frauenklinik Universitätsklinikum Tübingen Germany (1)
Head of the Curie Institute Mass Spectrometry Platform (1)
Head, Department of Biotechnology, University of Kashmir (1)
Institute of Molecular Medicine and Cell Research University of Freiburg Germany (1)
Johns Hopkins University, School of Medicine, Department of Pathology (1)
Laboratory of Angiogenesis and Vascular Metabolism, VIB Center for Cancer Biology (CCB), VIB, Leuven, Belgium. Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology and Leuven Cancer Institute (LKI), KU Leuven, Leuven, Belgium. (1)
Leibniz-Institut für Analytische Wissenschaften – ISAS – e.V. (1)
PRISM - Unité INSERM 1192 Université de Lille France (1)
Paul Scherrer Institute, Center for Radiopharmaceutica Sciences, 5232 Villigen PSI, Switzerland (1)
Professor & Head, Manipal Centre for Biotherapeutics Research, Manipal Academy of Higher Education, Karnataka, Manipal, 576 104, India (1)
Proteome Platform, University of Bordeaux, F-33076, Bordeaux, France. (1)
School of Life Sciences, Gwangju Institute of Science and Technology, 123 Cheomdangwagiro, Buk-gu, Gwangju 61005, Republic of Korea. (1)
School of Chinese Integrative Medicine, Hebei Medical University, Shijiazhuang, China (1)
Sydney Pharmacy School, The University of Sydney, NSW 2006, Australia (1)
Translational Biomedical Proteomics, Institute of Molecular and Cell Biology, Singapore (1)
Unit of Chemical Proteomics, Division of Chemistry I, Dept. of Medical Biochemistry and Biophysics (MBB), Karolnska Institutet, Biomedicum, Solna, Sweden (1)
University of Cadiz (1)
University of Milan (1)
University of Padua (1)

Keyword

Thalidomide (2)
Endostar (2)
Endostar protein (2)
Endostatins (2)
Famitinib (2)
Advanced Colorectal Cancer (2)
Irinotecan (2)
Bevacizumab (2)
Interleukin 1 Receptor Antagonist Protein (1)
Surgery,Crohn’s disease,Ulcerative colitis (1)
Anti-angiogenesis Drugs (1)
Vascular Endothelial Growth Factor A (1)
Chlorotrianisene (1)
Transarterial chemoembolization (1)
Anti-angiogenesis (1)
Embolics (1)
Advanced Colorectal Cancer and Other Gastrointestinal Cancers (1)
AV-951 (1)
Phase II (1)
Tivozanib (1)
Dose escalation (1)
Liver Metastases (1)
Efficacy (1)
Nintedanib (1)
FOLFIRI (1)
CRC (1)
Capecitabine (1)
Apatinib (1)
Celecoxib (1)
Leucovorin (1)

IsPrivate

False (1)

Study type

Transcription profiling by array (101)
Interventional (13)
RNA-seq of coding RNA (5)
Unknown experiment type (3)
RNA-seq of coding RNA from single cells (3)
Methylation profiling by high throughput sequencing (2)
Observational (2)
ChIP-chip by tiling array (1)
RNAi profiling by array (1)
ChIP-chip by array (1)
Transcription profiling by RT-PCR (1)
ChIP-seq (1)
RNA-seq of non coding RNA (1)
Observational patient registry (1)
Other (1)

Release Date

2022 (447)
2023 (408)
2021 (406)
2025 (383)
2020 (334)
2024 (307)
2019 (274)
2017 (251)
2016 (225)
2018 (212)
2015 (184)
2014 (156)
2013 (129)
2012 (99)
2026 (71)
2011 (68)
2010 (67)
2009 (49)
2008 (36)
2007 (15)
2006 (12)
2005 (6)
2004 (3)
2001 (2)
2003 (1)
2002 (1)
1998 (1)

Location

China (9)
France (2)
United States (2)
Taiwan (1)
Denmark (1)
Italy (1)
Netherlands (1)

Previous page
1 / 478
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 478
Next page

Sort by:

Relevance

Page size

Synergistic anti-tumor activity by association of MEK and PI3K/mTOR blockade with TRAIL in human melanoma

Combining direct anti-tumor effects with targeting of tumor microenvironment is an attractive strategy that may lead to more effective therapies for advanced melanoma. Here, we tested whether association of TRAIL with co-targeting of MEK and PI3K/mTOR, or with MEK blockade, could have synergistic a...

ORGANISM(S): Homo sapiens

2014-10-08 | E-GEOD-55050 | biostudies-arrayexpress

Isolation and Characterization of ZK002, A Novel Dual Function Snake Venom Peptide from Deinagkistrodon acutus with Anti-angiogenic and Anti-inflammatory Properties

Pathological angiogenesis, the abnormal or excessive generation of blood vessels, plays an important role in many diseases including cancer, diabetic retinopathy, psoriasis, and arthritis. Additionally, increasing evidence supports the close linkage between angiogenesis and inflammation. Snake venom...

ORGANISM(S): Deinagkistrodon acutus

2023-10-24 | PXD037093 | Pride

Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA)

Background: Docosahexaenoic acid (DHA) is a natural compound with anticancer and anti-angiogenesis activity that is currently under investigation as both a preventative agent and an adjuvant to breast cancer therapy. However, the precise mechanisms of DHA’s anticancer activities are unclear. It is u...

ORGANISM(S): Homo sapiens

2015-07-01 | E-GEOD-70432 | biostudies-arrayexpress

Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.

Not available

S-EPMC9843448 | biostudies-literature

Fibrinogen-derived fibrinostatin inhibits tumor growth through anti-angiogenesis.

Not available

S-EPMC4714678 | biostudies-literature

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.

Not available

S-EPMC3508273 | biostudies-literature

Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.